Looks like Biogen is in talks to register BIIB0114 with the FDA
 

Two questions:

Does this mean it's available to us while an eventual Phase III is ongoing?

Is this not the very first non-dopaminergic compound (BIIB014 is an adenosine receptor antagonist) that will be available to us?

http://www.medadnews.com/News/Index....ticleid=614883

"Biogen Idec also announced that it is currently in discussion with regulators surrounding the design of a registration program of BIIB014 in this patient population."

Good news
 

As one who took istradefylline (the now-defunct KW6002) for about three years, I would welcome the opportunity to try another adenisone receptor antagonist.

Jaye

The Parkinson Pipeline Project has been tracking a number of adenosine receptor antagonists in the pipeline. BIIB014 is the furthest along ,except for KW6002 (no longer available for trials in the U.S.), but o think they are talking about registering a Phase III trial. You can find out about this one and the others in the PPP database. Registration is no longer required.
Go to pdpipeline.org
Click on Database Access
On the Scorecard click on the Treatment Class heading. Scroll down. All of the adenisone receptor antagonists will be listed together.
Click on the treatment name for the database record.

Jaye:

Did you think you derived some benefit from it?

Cal